Praxis Precision Medicines Inc (PRAX) Stock Price, Quote & News

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

R84877P May. 20 at 1:46 PM

$PRAX Ready for $350 again

0 · Reply

Quantumup May. 20 at 11:34 AM

Piper Sandler⬆️ $DRUG's PT to $220, reit'd at Overweight/said—We caught up with DRUG following earnings, where mgmt reflected confidence in the progress made across programs this past quarter. SLNO - NBIX HRMY $RYTM LBPH - HLUBF / HLBBF PFE UCBJY STOK - BIIB JAZZ $PRAX XENE OVID Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2057061836768329992?s=20

0 · Reply

AIBioScanner May. 19 at 6:38 PM

$PRAX AI-Based Findings on PRAX After running PRAX through my AI-driven quantitative framework, the stock is in a sideways/mixed trend with price trading near both moving averages with no clear directional pressure. PRAX is trading around $323.46, near both the 20-day (~$332.85) and 50-day (~$319.92) moving averages — indicating indecision and softening structure. Key signals: • Trading near both MAs — sideways/mixed trend • MACD positive (2.64) — bullish momentum • Range between ~$316.14 support and ~$347.55 resistance 1-Month Outlook: Base scenario: consolidation near $307.29–$339.64 Breakout above $339.64 could open a move toward $397.38 Breakdown below $307.29 may extend further downside toward $251.98 Structure is neutral-to-mixed. Requires strong volume confirmation for any reversal. Not financial advice.

1 · Reply

R84877P May. 19 at 2:11 PM

$PRAX Hell yeah - buying! Can't wait until SEPT!

0 · Reply

Quantumup May. 19 at 10:36 AM

Truist assumed coverage on $RAPP and said: We are assuming coverage of RAPP with the firm's prior BUY rating and are raising our price target to $56 (from $44). $PRAX MPLT ALKS BHVN JAZZ VNDA UCBJY $XENE Truist added—Our thesis is largely consistent with the firm's most recent published view: we see RAP-219 as an attractive, differentiated epilepsy asset, with early efficacy data suggestive of best-in-category potential in focal onset seizures (FOS). We also see upside optionality in bipolar mania, which is not reflected in our current projections.

0 · Reply

Trainguy1 May. 18 at 11:10 PM

$PRAX I didn’t expect to buy any more PRAX, but when it dropped to $315/sh my bargain shopping instinct kicked in, and I was able to buy 50 shares. Can we expect PRAX return to $355 this week? I think so.

0 · Reply

R84877P May. 18 at 5:03 PM

$PRAX Every day $347 premarket and then drops to $319. I love this game we play 🙄I'm just patiently waiting for the breakout

0 · Reply

xabazzo May. 18 at 3:49 PM

$PRAX WTF! bad feeling after OPEX. That ~$350 level is hard to break!

0 · Reply

TornadoChasers May. 15 at 5:23 PM

$PRAX 9 mil shareS?

0 · Reply

R84877P May. 14 at 12:42 PM

$PRAX Slay

0 · Reply

Praxis Precision assumed with a Buy at Truist

May 12, 2026, 7:20 PM EDT - 7 days ago

Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 4:15 PM EDT - 12 days ago

Praxis Precision Medicines Q1 Earnings Call Highlights

2026-05-08T16:03:31.000Z - 12 days ago

Praxis Precision price target lowered to $420 from $444 at Deutsche Bank

2026-05-08T13:50:27.000Z - 12 days ago

Praxis Precision price target raised to $166 from $130 at Wedbush

May 7, 2026, 8:30 AM EDT - 13 days ago

Praxis Precision Medicines Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 13 days ago

Praxis Precision Medicines Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 13 days ago

Praxis Precision Medicines Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 13 days ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 13 days ago

Praxis Precision Medicines Slides: Corporate presentation

May 5, 2026, 4:01 PM EDT - 15 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026, 4:01 PM EDT - 16 days ago

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Apr 30, 2026, 8:00 AM EDT - 20 days ago

Praxis Precision Medicines Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 20 days ago

Praxis Precision Medicines Proxy statement: Proxy filing

2026-04-15T12:48:12.000Z - 5 weeks ago

Praxis Precision price target raised to $437 from $412 at Deutsche Bank

2026-04-14T11:42:59.000Z - 5 weeks ago

Praxis Precision announces FDA acceptance of ulixacaltamide NDA

Apr 14, 2026, 7:30 AM EDT - 5 weeks ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

2026-04-10T09:40:21.000Z - 5 weeks ago

Praxis Precision initiated with a Strong Buy at Raymond James

2026-04-09T20:30:17.000Z - 5 weeks ago

Praxis Precision initiated with a Strong Buy at Raymond James

2026-04-06T12:05:07.000Z - 6 weeks ago

Praxis Precision announces topline results from EMBRAVE Part A trial

Apr 6, 2026, 8:00 AM EDT - 6 weeks ago

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

2026-03-30T20:24:25.000Z - 7 weeks ago

Praxis Precision announces FDA acceptance for priority review of relutrigine NDA

Mar 30, 2026, 4:01 PM EDT - 7 weeks ago

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Mar 2, 2026, 11:50 AM EST - 2 months ago

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-23T21:16:33.000Z - 3 months ago

Praxis Precision initiated with an Outperform at Wolfe Research

2026-02-20T14:51:00.000Z - 3 months ago

Praxis Precision price target raised to $700 from $500 at Truist

2026-02-20T13:21:10.000Z - 3 months ago

Praxis Precision price target raised to $130 from $95 at Wedbush

2026-02-20T12:41:32.000Z - 3 months ago

Praxis Precision price target raised to $412 from $357 at Deutsche Bank

2026-02-20T12:07:25.000Z - 3 months ago

Praxis Precision price target raised to $433 from $275 at Baird

2026-02-20T11:32:20.000Z - 3 months ago

Praxis Precision price target raised to $305 from $282 at Wells Fargo

Feb 19, 2026, 8:00 AM EST - 3 months ago

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 3 months ago

Praxis Precision Medicines Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 3 months ago

Praxis Precision Medicines Annual report: Q4 2025

Feb 19, 2026, 7:30 AM EST - 3 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 3 months ago

Praxis Precision Medicines Slides: Corporate presentation

Feb 11, 2026, 1:00 PM EST - 3 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 4:01 PM EST - 3 months ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 2, 2026, 9:57 AM EST - 3 months ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Jan 22, 2026, 10:26 AM EST - 4 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 7:00 AM EST - 4 months ago

Praxis Precision Medicines Slides: Corporate presentation

Jan 8, 2026, 4:45 PM EST - 4 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 6, 2026, 11:15 PM EST - 4 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 4:03 PM EST - 4 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Dec 29, 2025, 8:00 AM EST - 5 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 11, 2025, 8:00 AM EST - 5 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 9, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 4, 2025, 4:10 PM EST - 5 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Nov 24, 2025, 1:00 PM EST - 6 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 20, 2025, 4:01 PM EST - 6 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 18, 2025, 8:30 AM EST - 6 months ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 6 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:00 AM EST - 6 months ago

Praxis Precision Medicines Slides: Corporate Presentation

Nov 7, 2025, 12:30 PM EST - 6 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 5, 2025, 8:00 AM EST - 7 months ago

Praxis Precision Medicines Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 7 months ago

Praxis Precision Medicines Quarterly report: Q3 2025

Nov 3, 2025, 9:58 AM EST - 7 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 16, 2025, 11:45 PM EDT - 7 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 2:14 PM EDT - 7 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 12:02 PM EDT - 7 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 8:00 AM EDT - 7 months ago

Praxis Precision Medicines Transcript: Study Result

Oct 16, 2025, 8:00 AM EDT - 7 months ago

Praxis Precision Medicines Press release: Study Result

Oct 16, 2025, 8:00 AM EDT - 7 months ago

Praxis Precision Medicines Slides: Study Result

Oct 16, 2025, 7:09 AM EDT - 7 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

Sep 29, 2025, 7:00 AM EDT - 8 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 10, 2025, 8:30 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:01 PM EDT - 9 months ago

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 2, 2025, 10:00 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Aug 25, 2025, 4:01 PM EDT - 9 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 7, 2025, 11:00 AM EDT - 10 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 5, 2025, 5:50 PM EDT - 10 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 10:00 AM EDT - 10 months ago